At the Euretina congress, Timothy L. Jackson, PhD, MBChB, discussed the phase 2b trial results of sozinibercept for neovascular age-related macular degeneration. Sozinibercept targets VEGF-C and VEGF-D and is used in combination with VEGF-A-suppressing drugs. The trial showed that the higher dose of sozinibercept, in combination with ranibizumab, had superior efficacy compared to ranibizumab alone. This drug offers improved visual acuity rather than just reducing injections. Phase 3 trials are underway to further evaluate sozinibercept’s effectiveness in combination with ranibizumab and aflibercept. Jackson reports consulting for Opthea.
Source link
Sozinibercept combination therapy shows promising visual acuity gains in wet AMD
